XP 21279

Drug Profile

XP 21279

Alternative Names: 279/CD; Levodopa prodrug - XenoPort; XP-21279; XP21279/carbidopa

Latest Information Update: 08 Sep 2015

Price : $50

At a glance

  • Originator XenoPort
  • Class Antiparkinsonians; Catecholamines
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 30 Jun 2015 Phase II development is ongoing in USA
  • 30 Jun 2015 XenoPort is still considering partnering opportunities for the development and commercialisation of XP 21279 outside USA. http://www.xenoport.com/
  • 24 Apr 2013 XenoPort is considering partnering opportunities for the development and commercialisation of XP 21279 outside USA. http://www.xenoport.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top